Trial reportBritish journal of clinical pharmacology1994
Nitric oxide mediated venodilator effects of nebivolol.
Trial report in British journal of clinical pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 190 citations in OpenAlex.
- Trial
- Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension.Hypertension (Dallas, Tex. : 1979) · 2014Trial
- Effects of metoprolol and nebivolol on exercise blood pressure in patients with mild hypertension.TheScientificWorldJournal · 2013Trial
- Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension.Journal of human hypertension · 2010Trial
- The efficacy and tolerability of nebivolol in hypertensive African American patients.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.British journal of clinical pharmacology · 2007Trial
- Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.British journal of clinical pharmacology · 2001Trial
- Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man in vivo.British journal of clinical pharmacology · 1998Trial
- Pharmacological properties of nebivolol in man.European journal of clinical pharmacology · 1997Trial
- Predictors of graft patency following coronary artery bypass graft surgery: the role of nebivolol therapy.GeroScience · 2025Article
- Adrenoceptors and Hypertension.Handbook of experimental pharmacology · 2024Review
- Novel Combined Antioxidant Strategy against Hypertension, Acute Myocardial Infarction and Postoperative Atrial Fibrillation.Biomedicines · 2021Review
- Biased agonism at β-adrenergic receptors.Cellular signalling · 2021Review
- A Novel function of Nebivolol: Stimulation of Adipose-derived Stem Cell Proliferation and Inhibition of Differentiation.Journal of stem cells & regenerative medicine · 2020Article
- GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.Cellular signalling · 2018Review
- The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.Pharmacological reviews · 2017Review
- Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia.The Biochemical journal · 2016Article
- The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i.PloS one · 2016Article
- Review
- Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Journal of the American Heart Association · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Nebivolol, a selective beta 1-adrenoceptor antagonist with antihypertensive effects, has haemodynamic effects suggestive of a direct vasodilator action. 2. The dorsal hand vein technique was used to determine whether nebivolol has venodilator action in vivo in man. 3. Nebivolol and atenolol were infused into the phenylephrine preconstricted superficial hand veins of 11 healthy male volunteers. In separate studies L-NMMA (0.1 microgram min-1) was pre- and co-infused with nebivolol to determine whether nitric oxide (NO) mediated mechanisms were present. Further studies with prostaglandin F2 alpha (PGF2 alpha) preconstriction were performed to exclude an alpha-adrenergic antagonistic effect of nebivolol. Effects of L-NMMA infusion on nitroglycerin venodilation were also determined. 4. Nebivolol produced a dose dependent venodilation, (72 +/- 18% maximum), whereas atenolol produced no significant venodilation. At doses of nebivolol producing plasma concentrations comparable with plasma levels achieved after standard oral dosing (10(-13)-10(-12) mol min-1) small (14 +/- 6% and 23 +/- 8%) but significant (P < 0.05) venodilation was observed. 5. The venodilator response to nebivolol was significantly reduced by infusion of L-NMMA (maximum dilation 18% vs 72%, P < 0.01). Venodilator responses to nitroglycerin were unaffected by L-NMMA infusion. A venodilator effect to nebivolol was also seen following preconstriction with PgF2 alpha (40 +/- 20% maximum). 6. Nebivolol has nitric oxide mediated, venodilator effects in man.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.